Pyrroloazepine derivatives

ABSTRACT

Disclosed herein are pyrroloazepine derivatives having anti-α 1  activity and anti-serotonin activity represented by the following formula (I): ##STR1## wherein R means a hydrogen atom, a linear or branched C 1-6  alkyl group or a C 7-10  aralkyl group, A denotes a linear or branched C 2-10  alkylene, alkenylene or alkynylene group, Z stands for O, NOR 1  or NOCOR 5  in which R 1  and R 5  is a hydrogen atom or an alkyl, aryl or aralkyl group, and Y means a particular piperidinyl or pyrrolidinyl group; and salts thereof. Their preparation processes are also disclosed.

This is a Continuation Application of application Ser. No. 07/987,703filed Dec. 9, 1992 which is a divisional of Ser. No. 07/651,778 filedFeb. 7, 1991, now U.S. Pat. No. 5,206,239.

BACKGROUND OF THE INVENTION

1. Field of the Invention

The present invention relates to novel pyrroloazepine derivatives, andmore specifically to novel pyrroloazepine derivatives and salts thereof,said derivatives and salts having strong anti-α₁ action andanti-serotonin action but low toxicity and being useful as therapeuticsfor circulatory diseases such as hypertension and congestive heartfailure, their preparation processes thereof and therapeutics forcirculatory diseases, said therapeutics containing them as activeingredients.

2. Description of the Prior Art

Numerous substances have heretofore been known as drugs which act on thecirculatory system. Among these, a variety of substances have beendeveloped as antihypertensive drugs.

Of such antihypertensive drugs, α₁ -blockers represented by prazosinhave such merits that (1) their antihypertensive action is strong andsure, (2) they do not give adverse influence to the lipidometabolic andglycometabolic systems and (3) they can be easily used for hypertensiveshaving complication. Their development is hence actively under way.Clinically-applied examples of such α₁ -blockers include bunazosin,doxazosin, terazosin and urapidil in addition to prazosin.

α₁ -Blockers are however accompanied by the drawback that they generallyhave side effects such as orthostatic disorder and reflex tachycardia,tend to induce orthostatic hypotension especially when administered toaged people and hence require attention.

As a drug having less tendency of inducing such side effects of α₁-blockers, ketanserin having both anti-serotonin action and anti-α₁action has been developed as a drug effective for senile hypertensionand the like.

However, this ketanserin may not be able to exhibit, for example,sufficient hypotensive action in some instances, and its side effects tothe central nervous system such as drowsiness and sedative action haveposed problems.

SUMMARY OF THE INVENTION

In view of the foregoing circumstances, the present inventorssynthesized numerous compounds and investigated their pharmacologicaleffects with a view toward obtaining drugs having both anti-serotoninaction and anti-α₁ action, strong hyportensive action, and low sideeffects and toxicity.

As a result, the compounds represented by the below-described formula(I) having the pyrroloazepine structure have been found to meet theabove requirements, leading to the completion of the present invention.

This invention therefore provides a pyrroloazepine derivativerepresented by the following formula (I): ##STR2## wherein R means ahydrogen atom, a linear or branched C₁₋₆ alkyl group or a C₇₋₁₀ aralkylgroup, A denotes a linear or branched C₂₋₁₀ alkylene, alkenylene oralkynylene group, Z stands for O, NOR₁ in which R₁ is a hydrogen atom oran alkyl, aryl or aralkyl group, or NOCOR₅ in which R₅ is a hydrogenatom or an alkyl, aryl or aralkyl group, and Y means a group ##STR3## inwhich R₂ means a hydrogen atom or a cyano group, R₃ an R'₃ may be thesame or different and individually denote a substituted or unsubstitutedphenyl group or a substituted or unsubstituted aralkyl group, and B isan oxygen or sulfur atom or a carbonyl, substituted or unsubstitutedhydroxymethylene, sulfinyl, sulfonyl or substituted or unsubstituted,cyclic or acyclic acetal, and n stands for 0 or 1, or a salt thereof; apreparation process thereof: and a therapeutic for circulatory diseases,said therapeutic comprising as active ingredient the pyrroloazepinederivative or the salt thereof.

The pyrroloazepine derivatives (I) and their pharmacologicallyacceptable salts according to the present invention are drugs havinganti-α₁ action and anti-serotonin action and have a high degree ofsafety. They can therefore be used, for example, as novel therapeuticsfor circulatory diseases.

DETAILED DESCRIPTION OF THE INVENTION AND PREFERRED EMBODIMENTS

In the pyrroloazepine derivative (I) of the present invention, preferredexamples of group A include C₃₋₆ alkenyl groups such as --CH₂ CH═CHCH₂--, C₃₋₆ alkynyl groups such as CH₂ C.tbd.CCH₂ --, and (CH₂)_(n) (n:3-5). Preferred examples of group R include hydrogen atom, and methyl,ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl and benzylgroups. In addition, preferred examples of R₃ and R₃ ' include a phenylgroup; a phenyl group substituted by one or more halogen atoms such asfluorine, chlorine and bromine, and C₁₋₄ alkoxy groups such as methoxyand ethoxy groups; a benzyl group; and a diphenylmethyl group. When R₃and R₃ ' mean substituted aralkyl groups, each substituent may be bondedto either the aryl moiety or the alkyl moiety. When B stands for asubstituted hydroxymethylene group, exemplary substituents include loweralkyl groups such as methyl, ethyl and propyl; a phenyl group; and aphenyl group substituted by one or more halogen atoms such as fluorine,chlorine and bromine and C₁₋₄ alkoxy groups such as methoxy and ethoxygroups. Further, examples of the substituted or unsubstituted, cyclic oracyclic acetal represented by B include ##STR4## In addition, preferredexamples of group R₁ include hydrogen atom, lower alkyl groups such asmethyl group, and C₇₋₁₀ aralkyl groups such as benzyl group. Preferredexamples of R₅ include lower alkyl groups such as methyl groups and arylgroups such as phenyl group.

Where compounds according to the present invention have isomers, it isto be noted that these isomers are all embraced by the presentinvention. For example, when there is a hydroxyimino group or anO-substituted hydroxyimino group at 4-position of the pyrroloazepinering, there are both an (E)-isomer and a (Z) isomer with respect to thegroup. The compounds of the present invention also include theseindividual isomers and their mixtures.

The pyrroloazepine derivatives (I) according to the present inventioncan be prepared by a desired conventional method. However, thepyrroloazepine derivatives (I) are preferably prepared, for example, byany of the following processes:

(1) Among the pyrroloazepine derivatives (I), the compounds (Ia) inwhich Z represents O can each be obtained in accordance with thefollowing reaction scheme, namely, by converting the compoundrepresented by formula (II) to the compound represented by formula (III)and then reacting the nitrogen-containing cyclic compound represented byformula (IV) or a salt thereof with the compound (III). ##STR5## whereinA, R and Y have the same meanings as defined above, X means asubstituent easily replaceable with an amino group, and X' denotes ahydroxyl group or a substituent easily replaceable with an amino group.

The conversion from the compound (II) to the compound (III) is effectedby causing the compound represented by formula (V) to act on thecompound (II) in the presence of an organic or inorganic base. Examplesof the substituent, which is easily replaceable with an amino group, asgroup X in the compound (V) include halogen atoms such as chlorine andbromine atoms, methanesulfonyl group and p-toluenesulfonyl group. Anysolvent can be used in this reaction as long as it does not take part inthe reaction. Illustrative solvents include dimethylformamide,acetonitrile, dimethylsulfoxide, tetrahydrofuran, dioxane and acetone.Further, exemplary organic or inorganic bases include triethylamine,pyridine, collidine, 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), sodiumhydroxide, potassium hydroxide, sodium carbonate, potassium carbonate,sodium ethoxide, and potassium t-butoxide. The reaction is conducted at-20° C. to the reflux temperature.

To prepare the compound (Ia) by reacting the compound (III) with thenitrogen-containing cyclic compound (IV), it is only necessary to reactat room temperature to 150° C. the nitrogen-containing cyclic compound(IV) or an organic acid or inorganic acid salt thereof with the compound(III), optionally together with an organic base such as triethylamine,pyridine, collidine, DBU or potassium t-butoxide or an inorganic basesuch as potassium carbonate, sodium carbonate, potassium hydroxide orsodium hydroxide, optionally after adding an iodide such as sodiumiodide or potassium iodide.

Examples of the nitrogen-containing cyclic compound (IV) include4-phenylpiperidine, 4-benzylpiperidine,4-[bis(4-fluorophenyl)methylene]piperidine,α,α-bis-(4-fluorophenyl)-4-piperidinemethanol,4-(diphenylmethoxy)piperidine, 4-cyano-4-phenylpiperidine,4-(4-fluorobenzoyl)piperidine, 4-benzoylpiperidine,4-(4-methoxybenzoyl)piperidine, 4-(4-chlorobenzoyl)piperidine,3-(4-fluorobenzoyl)piperidine, 3-benzoylpyrrolidine,3-(4-fluorobenzoyl)pyrrolidine, 4-(4-fluorophenoxy)piperidine,4-[(4-fluorophenyl)thio]piperidine,4-[(4-fluorophenyl)sulfinyl]piperidine,4-[(4-fluorophenyl)sulfonyl]piperidine, and4-(4-fluorobenzoyl)piperidine ethyleneacetal. They are all either knowncompounds or compounds which can be readily prepared by a known processor a process similar to the known process.

Incidentally, among the compounds (II) employed as starting materials inthe above reaction, the compound in which R is H has been known but theremaining compounds are novel compounds. These novel compounds can eachbe prepared in accordance with the following reaction scheme, namely, byreacting a pyrrole-2-carboxylic acid or a derivative thereof representedby the formula (VI) with a β-amino acid or a derivative therofrepresented by the formula (VII) or an organic or inorganic salt of theβ-amino acid or the derivative thereof and optionally removing theprotecting group, thereby obtaining the compound represented by theformula (VIII) and then ring-closing this compound. ##STR6## wherein Rhas the same meaning as defined above, R₄ means a hydrogen atom or acarboxyl-protecting group, and W denotes a hydroxyl group or asubstituent easily replaceable with an amino group.

Examples of the substituent easily replaceable with an amino group asrepresented by W in the compound (VI) include halogen atoms, carboxylicacid residue and the like. On the other hand, as the carboxyl-protectinggroup, it is possible to use, in addition to lower alkyl groups such asmethyl, ethyl, propyl, isopropyl, n-butyl, isobutyl and t-butyl andC₇₋₂₀ aralkyl groups such as benzyl and 9-anthrylmethyl, theconventional protecting groups described by T. W. Greene in "ProtectiveGroups in Organic Synthesis" (John Wiley & Sons, Inc.) and the like. Forthe synthesis of the compounds (VIII), it is possible to use any one ofthe various processes disclosed in "Compendium for Organic Synthesis"(WILEY-INTERSCIENCE, a division of John Wiley & Sons, Inc.) and thelike. Exemplary processes include the process in whichpyrrole-2-carboxylic acid of the compound (VI) in which W is OH istreated with an organic compound such as diethyl cyanophosphonate(DEPC), diphenylphosphoryl azide (DPPA), dicyclohexylcarbodiimide (DCC),1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride or2-iodo-1-methylpyridinium iodide or an inorganic compound such assilicon tetrachloride or tin tetrachloride, if necessary, in thepresence of an organic or inorganic base; and the process in whichpyrrole-2-carboxylic acid is reacted after converting it to its acidhalide, symmetric acid anhydride, mixed acid anhydride or its activeester such as p-nitrophenyl ester or to a like compound.

Each compound (VIII) thus obtained is subjected to a cyclizing reaction,optionally after removing the protecting group by virtue of a suitablemethod such as the action of an acid or a base, or catalytic reduction.This cyclizing reaction is conducted by treating the compound (VIII)together with an organic acid such as methanesulfonic acid, an inorganicacid such as sulfuric acid or polyphosphoric acid or a mixture of suchan organic or inorganic acid and diphosphorus pentoxide at roomtemperature to 170° C., preferably at 80°-120° C. In this case, asolvent which does not take part in the reaction may be added as needed.As an alternative, the cyclizing reaction can also be practiced bytreating the compound (VIII) with oxalyl chloride, thionyl chloride,thionyl bromide, oxalyl bromide, phosgene, phosphorus trichloride,phosphorus tribromide, phosphoryl chloride, phosphoryl bromide or thelike, optionally in the presence of a catalyst to convert the compound(VIII) to its corresponding acid halide and then treating the acidhalide at -20° C. to reflux temperature in the presence of a Lewis acidsuch as aluminum chloride, aluminum bromide, boron trifluoride-ethercomplex or tin tetrachloride in a solvent such as dichloromethane,1,2-dichloroethane or nitromethane or heating the acid halide in aceticacid.

The compounds (II) obtained in the above manner can be used directly asstarting materials for the preparation of the compounds (Ia) of thepresent invention. They can also be used after purification by aconventional purification method, for example, by recrystallization orcolumn chromatography if necessary.

(2) Among the pyrroloazepine derivatives (I), the compounds (Ib) inwhich Z is represented by NOR₁ can each be prepared in accordance withthe following reaction formula, namely, (i) by causing a hydroxylamineor a derivative therof represented by the formula (IX) or or a salt ofthe hydroxylamine or the derivative to act on the compound (Ia) obtainedby the above-described reaction or (ii) by causing the hydroxylamine orits derivative (IX) or a salt of the hydroxylamine or the derivative toact on the compound (III) and then causing a nitrogen-containing cycliccompound (IV) or a salt thereof to act further. ##STR7## wherein A, R,R₁, X and Y have the same meanings as defined above.

The reaction between the compound (Ia) or (III) and the hydroxylamine orits derivative (IX) is practiced, if necessary, in the presence of anorganic base such as pyridine, triethylamine, collidine, DBU or sodiumacetate or an inorganic base such as potassium carbonate or sodiumhydroxide. The hydroxylamine or its derivative (IX) may also be used inthe form of an organic acid salt or an inorganic acid salt.

The compound (X) obtained by the reaction of the compound (III) with thecompound (IX) can be reacted further with the nitrogen-containing cycliccompound (IV) by the method described above, whereby the compound (X)can be converted to the compound (Ib).

Upon preparation of the compound (Ib), it is determined depending on thestructure and properties of the nitrogen-containing cyclic compound (IV)whether the hydroxylamine or its derivative (IX) should be reacted tothe compound (III) or to the compound (Ia). Where there is a groupreactive to the hydroxylamine or its derivative (IX), such as a carbonylgroup, in the nitrogen-containing cyclic compound (IV), it is desirableto choose the process that the hydroxylamine or its derivative (IX) isreacted to the compound (III).

(3) Among the pyrroloazepine derivatives (I), the compounds (Ic) inwhich X is represented by ##STR8## can each be prepared (i) by acylatingthe compound (Ib') [i.e., the compound of formula (Ib) in which R₁ isH)], which has been obtained by the above reaction formula, with acarboxylic acid or its derivative represented by formula (XI) or (ii) byacylating the compound (X') [i.e., the compound of formula (X) in whichR₁ is H)] with a carboxylic acid or its derivative represented byformula (XI) and then causing a nitrogen-containing cyclic compound (IV)or its salt to act further. ##STR9## wherein A, R, X and Y have the samemeanings as defined above, R₅ means a hydrogen atom or an alkyl, aryl oraralkyl group, and X" denotes a hydroxyl group or an eliminativesubstituent easily reactable with a hydroxyimino group.

Illustrative of the eliminative group (X") easily reactable with ahydroxyimino group include cyano group, halogen atoms such as Cl and Br,p-nitrophenoxy group, and those represented by the formula ##STR10##wherein R₆ means an alkyl, aryl, aralkyl, alkoxyl or aryloxyl group.

The reaction between the compound (Ib') or (X') with the carboxylic acidor its derivative represented by the formula (XI) can be conducted usingany one of the various esterification processes described in "Compendiumof Organic Synthetic Methods" (WILEY-INTERSCIENCE, a division of JohnWiley & Sons, Inc.) and the like.

Examples include the process in which the compound (Ib') or (X') and thecarboxylic acid represented by the formula (XI') [the compound offormula (XI) in which X" is OH] are condensed with diethylcyanophosphonate (DEPC), diphenylphosphoryl azide (DPPA),dicyclohexylcarbodiimide (DCC),1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride,2-iodo-1-methylpyridinium iodide or the like, if necessary in thepresence of an organic base such as triethylamine, pyridine, collidine,DBU or sodium acetate or an inorganic base such as potassium carbonateor sodium hydroxide; and the process in which the acid haliderepresented by the formula (XI") [the compound of (XI) in which X" is ahalogen atom such as chlorine or bromine] is reacted to the compound(Ib') or (X'), if necessary in the presence of the above-describedorganic or inorganic base.

If necessary, the compounds (I) of the present invention obtained asdescribed above can be reacted with various acids or alkylating oraralkylating agent to convert the compounds (I) to theirpharmacologically acceptable salts, followed by purification byrecrystallization or column chromatography and the like.

Exemplary acids usable to convert the pyrroloazepine derivatives (I) totheir salts include inorganic acids such as hydrochloric acid, nitricacid, sulfuric acid, phosphoric acid and hydrobromic acid; and organicacids such as maleic acid, fumaric acid, tartaric acid, oxalic acid,lactic acid, citric acid, acetic acid, methanesulfonic acid,p-toluenesulfonic acid, adipic acid, palmitic acid and tannic acid.

In addition, other exemplary salts of the compounds (I) of the presentinvention include their quaternary ammonium salts, which are obtained bycausing an alkylating agent. Usable examples of the alkylating agentinclude C₁₋₁₀ alkyl halides, C₇₋₁₂ aralkyl halides, dialkyl sulfates andthe like. Exemplary C₁₋₁₀ alkyl halides include methyl chloride, ethylchloride, methyl bromide, ethyl bromide, methyl iodide and ethyl iodideand exemplary C₇₋₁₂ aralkyl halides include benzyl chloride and benzylbromide, while illustrative dialkyl sulfates include dimethyl sulfateand diethyl sulfate.

The pyrroloazepine derivatives (I) and their salts, which are obtainedas described above, have anti-α₁ action and anti-serotonin action aswill be demonstrated later by tests. Further, their LD₅₀ values are ashigh as at least 300 mg/kg (p.o) so that they have a high degree ofsafety. The compounds according to the present invention can thereforebe used as therapeutics for circulatory diseases such as hypertensionand congestive heart failure.

When the pyrroloazepine derivatives (I) and their salts are used asdrugs, they can be administered in an effective dose as they are. As analternative, they can also be formulated into various preparation formsby known methods and then administered.

Exemplary preparation forms as drugs include orally administeringpreparation forms such as tablets, powders, granules, capsules andsyrups as well as parenterally administering preparation forms such asinjections and suppositories. Whichever preparation form is used, aknown liquid or solid extender or carrier usable for the formulation ofthe preparation form can be employed.

Examples of such extender or carrier include polyvinylpyrrolidone,arabic gum, gelatin, sorbit, cyclodextrin, tragacanth, magnesiumstearate, talc, polyethylene glycol, polyvinyl alcohol, silica, lactosesugar, crystalline cellulose, starch, calcium phosphate, vegetable oil,carboxymethylcellulose, sodium laurylsulfate, water, ethanol, glycerin,mannitol, and syrup.

The present invention will next be described in further detail by thefollowing examples and tests.

Example 1

Synthesis of benzyl 3-(2-pyrrolecarboxamido)propionate (Compound No. 1)

A solution of 5.34 g (48.1 mmol) of pyrrole-2-carboxylic acid and 18.59g (52.9 mmol) of β-alanine benzyl ester tosylate in 100 ml ofdimethylformamide (DMF) was cooled to 0° C., followed by the addition ofa solution of 9.42 g (57.7 mmol) of diethyl cyanophosphate in 20 ml ofDMF under stirring. After a solution of 11.68 g (115.4 mmol) oftriethylamine in 20 ml of DMF was gradually added further dropwise, theresultant mixture was stirred for 40 hours at room temperature.

A mixed solvent (400 ml) of ethyl acetate and benzene (2:1 v/v) wasadded to the reaction mixture. The organic layer was washed successivelywith a saturated aqueous solution of sodium hydrogencarbonate, water(three times) and saturated saline, followed by drying over anhydroussodium sulfate.

The solvent was distilled off under reduced pressure and the resultantsolid was recrystallized from chloroform-isopropyl ether, whereby 11.65g of the title compound were obtained (yield: 95%).

Appearance: Colorless prism crystals.

Melting point: 82°-83° C.

Example 2

Synthesis of ethyl 3-(N-methyl-2-pyrrolecarboxamido)propionate (CompoundNo. 2)

A solution of 50.0 g (450 mmol) of pyrrole-2-carboxylic acid and 64.9 g(495 mmol) of ethyl 3-(methylamino)propionate in 200 ml ofdimethylformamide (DMF) was cooled to 0° C., followed by the addition ofa solution of 80.8 g (495 mmol) of diethyl cyanophosphate in 100 ml ofDMF under stirring. After a solution of 50.1 g (495 mmol) oftriethylamine in 100 ml of DMF was added dropwise at the sametemperature over 1 hour, the resultant mixture was stirred for 18 hoursat room temperature.

To an oil obtained by concentrating the reaction mixture under reducedpressure, 1200 ml of a mixed solvent of ethyl acetate and benzene (3:1v/v) was added. The organic layer was washed successively with asaturated aqueous solution of potassium carbonate, water, 5%hydrochloric acid solution water (twice) and saturated saline, followedby drying over anhydrous sodium sulfate. To an oil obtained bydistilling off the solvent under reduced pressure, isopropyl ether (200ml) and hexane (1000 ml) were added. After the resultant mixture wasshaken, it was allowed to stand for one day.

Precipitated crystals were collected by filtration and then dried underreduced pressure, whereby 87.5 g of the title compound were obtained ascolorless glossy crystalline powder (yield: 87%).

Although this compound is sufficiently pure, it can be recrystallizedfrom isopropyl ether if necessary.

Appearance: Colorless prism crystals.

Melting point: 57°-58° C.

Example 3

The following compounds (Compound No. 3, 4, 5 and 7) were obtained byusing ethyl 3-(ethylamino)propionate, ethyl 3-(propylamino)propionate,ethyl 3-(isopropylamino)propionate and ethyl 3-(benzylamino)propionatein place of ethyl 3-(methylamino)propionate in the procedure describedin Example 2.

(Compound No. 3)

Ethyl 3-(N-ethyl-2-pyrrolecarboxamido)propionate

(Compound No. 4)

Ethyl 3-(N-propyl-2-pyrrolecarboxamido)propionate

(Compound No. 5)

Ethyl 3-(N-isopropyl-2-pyrrolecarboxamido)propionate

(Compound No. 7)

Ethyl 3-(N-benzyl-2-pyrrolecarboxamido)propionate

Example 4

Synthesis of ethyl 3-(N-methyl-2-pyrrolecarboxamido)propionate (CompoundNo. 2) (alternative process)

To a solution of 5.56 g (50 mmol) of pyrrole-2-carboxylic acid and onedroplet of DMF in 50 ml of tetrahydrofuran (THF) were added dropwise6.54 ml (75 mmol) of oxalyl chloride under stirring and ice cooling at0° C., and the resultant mixture was stirred for 2 hours at roomtemperature. The reaction mixture was concentrated under reducedpressure so that crystals of the acid chloride were obtained.

A solution of the above-obtained acid chloride in 40 ml of benzene wasslowly added dropwise under cooling and stirring to a solution of 6.56 g(50 mmol) of ethyl 3-(methylamino)propionate and 4.85 ml (60 mmol) ofpyridine in 20 ml of benzene. The resulting mixture was stirred for 30minutes at the same temperature and for additional 18 hours at roomtemperature. The reaction mixture was filtered and the filtrate wasconcentrated under reduced pressure. Upon recrystallization of theresultant crystals from isopropyl ether, 10.2 g of the title compoundwere obtained (yield: 91%).

Example 5

Synthesis of ethyl 3-(N-butyl-2-pyrrolecarboxamido)propionate (CompoundNo. 6)

The title compound was obtained by using ethyl 3-(butylamino)propionatein place of ethyl 3-(methylamino)propionate in the procedure describedin Example 4.

Example 6

Synthesis of 3-(N-methyl-2-pyrrolecarboxamido)propionic acid (Compound9)

A mixture of 37.00 g (165 mmol) of Compound No. 2 obtained in Example 2,413 ml (826 mmol) of 2N aqueous solution of sodium hydroxide and 20 mlof ethanol was stirred for 4 hours at room temperature. The reactionmixture was cooled, and 80 ml of concentrated hydrochloric acid wereadded under stirring, followed by further stirring. Precipitatedcrystals were then collected by filtration.

The filtrate was saturated with sodium chloride, followed by extractionwith ethyl acetate. The extract was dried over anhydrous sodium sulfateand the solvent was distilled off under reduced pressure, wherebycrystals were obtained.

Both crystals were combined and recrystallized from ethyl acetate,whereby 27.69 g of the title compound were obtained (yield: 86%).

Appearance: Colorless prism crystals.

Melting point: 125°-127° C.

Example 7

The following compounds (Compound Nos. 10, 11, 12, 13 and 14) wereobtained by using Compound Nos. 3, 4, 5, 6 and 7 in place of CompoundNo. 2 in the procedure described in Example 6.

(Compound No. 10)

3-(N-Ethyl-2-pyrrolecarboxamido)propionic acid

(Compound No. 11)

3-(N-Propyl-2-pyrrolecarboxamido)propionic acid

(Compound No. 12)

3-(N-Isopropyl-2-pyrrolecarboxamido)propionic acid

(Compound No. 13)

3-(N-Butyl-2-pyrrolecarboxamido)propionic acid

(Compound No. 14)

3-(N-Benzyl-2-pyrrolecarboxamido)propionic acid

Example 8

Synthesis of 3-(2-pyrrolecarboxamido)propionic acid (Compound No. 8)

Hydrogen was blown at atmospheric pressure into a suspension of 10.00 g(39.3 mmol) of Compound No. 1 obtained in Example 1 and 2.00 g of 5%palladium-carbon in 300 ml of THF while the suspension was stirred.After the full consumption of the starting material was confirmed bythin layer chromatography on silica gel (about 1 hour), the reactionmixture was filtered and an insoluble matter was washed with THF.

The filtrate and the washing were combined, and the solvent wasdistilled off under reduced pressure. The resulting solid wasrecrystallized from acetonitrile, whereby 5.61 g of the title compoundwere obtained (yield: 78%).

Appearance: Colorless prism crystals.

Melting point: 148°-150° C.

Example 9

Synthesis of 7-methyl-6,7-dihydropyrrolo[2,3-c]azepine-4,8(1H,5H)-dione(Compound No. 16)

A mixture of 7.00 g of Compound No. 9 obtained in Example 6 and 250 g ofpolyphosphoric acid (about 80%) was vigorously stirred for 30 minutes bya mechanical stirrer over an oil bath maintained at 100° C.

The reaction mixture was poured into 700 ml of ice water, followed byextraction with chloroform. The organic layer was washed with saturatedsaline (twice) and then dried over anhydrous sodium sulfate.

The solvent was distilled off under reduced pressure, whereby 5.58 g ofthe title compound were obtained as pale brown crystals (yield: 88%).

Although this compound is sufficiently pure, it can be recrystallizedfrom chloroform-isopropyl ether if necessary.

Appearance: Colorless needle crystals.

Melting point: 175°-177° C.

Example 10

The following compounds (Compound Nos. 15, 17, 18, 19 and 21) wereobtained by using Compound Nos. 8, 10, 11, 12 and 14 in place ofCompound No. 9 in the procedure of Example 9.

(Compound No. 15)

6,7-Dihydropyrrolo[2,3-c]azepine-4,8(1H,5H)-dione

(Compound No. 17)

7-Ethyl-6,7-dihydropyrrolo[2,3-c]azepine-4,8-(1H,5H)-dione

(Compound No. 18)

7-Propyl-6,7-dihydropyrrolo[2,3-c]azepine-4,8-(1H,5H)-dione

(Compound No. 19)

7-Isopropyl-6,7-dihydropyrrolo[2,3-c]azepine-4,8 (1H,5H) -dione

(Compound No. 21)

7-Benzyl-6,7-dihydropyrrolo[2,3-c]azepine-4,8-(1H,5H)-dione

Example 11

Synthesis of 7-butyl-6,7-dihydropyrrolo[2,3-c]azepine-4,8(1H,5H)-dione(Compound No. 20)

A mixture of 10.0 g (42.0 mmol) of Compound No. 13 and 200 g ofpolyphosphoric acid (about 80%) was vigorously stirred for 30 minutes bya mechanical stirrer over an oil bath maintained at 80° C. After 3.02 gof diphosphorus pentaoxide were added and the resultant mixture wasstirred for 1 minute, 10.0 g (42.0 mm) of Compound No. 13 were added andthe mixture thus formed was vigorously stirred for 30 minutes at thesame temperature.

The reaction mixture was poured into 750 ml of ice water, followed byextraction with chloroform. The organic layer was washed with saturatedsaline (twice) and then dried over anhydrous sodium sulfate.

The solvent was distilled off under reduced pressure, whereby 16.73 g ofthe title compound were obtained as pale brown crystals (yield: 91%).Appearance: Pale brown needle crystals.

Melting point: 115°-118° C.

Example 12

Synthesis of 7-methyl-6,7-dihydropyrrolo[2,3-c]azepine-4,8-(1H,5H)-dione(Compound No. 16) (alternative process)

A mixture of 329 mg (2 mmol) of Compound No. 9 obtained in Example 6 and15 ml of methanesulfonic acid was stirred for 40 minutes at 100° C. Thereaction mixture was allowed to cool down and then poured into 200 ml ofice water. The resultant mixture was adjusted to about pH 5 withpotassium carbonate and then saturated with sodium chloride. The aqueouslayer was extracted with chloroform. The extract was washed withsaturated saline and then dried over anhydrous sodium sulfate.

The solvent was distilled off under reduced pressure, whereby 337 mg ofthe title compound were obtained as a pale brown solid.

Although this compound is sufficiently pure, it can be recrystallizedfrom chloroform-isopropyl ether if necessary.

Example 13

Synthesis of 7-ethyl-6,7-dihydropyrrolo[2,3-c]azepine-4,8(1H,5H)-dione(Compound No. 17) (alternative process)

To a solution of 2.104 g (10 mmol) of Compound No. 10 in 30 ml of THF,1.523 g (12 mmol) of oxalyl chloride and 1 droplet of DMF were added atroom temperature under stirring. The resultant mixture was stirred for 3hours at the same temperature, and the solvent was distilled off underreduced pressure.

The residue was then dissolved in 100 ml of 1,2-dichloroethane, followedby the addition of 4.00 g (30 mmol) of ground aluminum chloride. Afterthe reaction mixture was heated at 50°-60° C. for 2 hours, the reactionmixture was stirred for 20 hours at room temperature. The reactionmixture was poured into 300 ml of ice water. The mixture thus preparedwas allowed to separate into water and organic layers. The aqueous layerwas extracted with chloroform. The extract and the organic layer werecombined together, washed with saturated saline, and dried overanhydrous sodium sulfate. The solvent was then distilled off underreduced pressure.

The resultant solid was purified by chromatography on a silica gelcolumn using as silica gel "Art. 9385" (product of Merck & Co.; the samesilica gel was also used in the subsequent examples) (eluent: 3:2 mixedsolvent of ethyl acetate and hexane), whereby 1.540 g of the titlecompound was obtained as a colorless solid (yield: 80%).

Although this compound is sufficiently pure, it can be recrystallizedfrom isopropanol if necessary.

Appearance: Colorless needle crystals.

Melting point: 131°-133° C.

Example 14

Synthesis of1-(4-chlorobutyl)-7-methyl-6,7-dihydropyrrolo[2,3-c]azepine-4,8(1H,5H)-dione(Compound 23)

A suspension of 2.67 g (15 mmol) of Compound No. 16 obtained in Example9, 7.62 g (60 mmol) of 1,4-dichlorobutane and 8.29 g (60 mmol) ofpotassium carbonate in 150 ml of DMF was stirred at 80° C. for 5 hours.

The reaction mixture was poured into 200 ml of 5% hydrochloric acid,followed by the addition of 500 ml of a mixed solvent of ethyl acetateand benzene (2:1, v/v). The resultant mixture was allowed to separateinto an organic layer and a water layer. The organic layer was washedwith water (three times) and saturated saline, and was then dried overanhydrous sodium sulfate.

The solvent was distilled off under reduced pressure. The resultant oilwas purified by chromatography on a silica gel column (eluent: 1:1 mixedsolvent of ethyl acetate and hexane), whereby 3.907 g of the titlecompound were obtained as colorless crystals (yield: 97%).

Although this compound is sufficiently pure, it can be recrystallizedfrom ethyl acetate-hexane if necessary.

Appearance: Colorless prism crystals.

Melting point: 59.0°-60.5° C.

Example 15

Compound Nos. 22, 30, 31, 32 and 34 were obtained by using Compound Nos.15, 17, 18, 19 and 21 in place of Compound No. 16 in the procedure ofExample 14.

Compound Nos. 24, 25, 26, 27, 28 and 29 were obtained by using CompoundNo. 16 and 1,4-dibromobutane, (Z)-1,4-dichloro-2-butene,(E)-1,4-dichloro-2-butene, 1,4-dichloro-2-butyne, 1,3-dichloropropaneand 1,5-dichloropentane in place of 1,4-dichlorobutane.

Compound No. 35 was obtained from the combination of Compound 21 and1,4-dibromobutane.

(Compound No. 22)

1-(4-Chlorobutyl)-6,7-dihydropyrrolo[2,3-c]azepine-4,8(1H,5H)-dione

(Compound No. 30)

1-(4-Chlorobutyl)-7-ethyl-6,7-dihydropyrrolo[2,3-c]azepine-4,8(1H,5H)-dione

(Compound No. 31)

1-(4-Chlorobutyl)-7-propyl-6,7-dihydropyrrolo[2,3-c]azepine-4,8(1H,5H)-dione

(Compound No. 32)

1-(4-Chlorobutyl)-7-isopropyl-6,7-dihydropyrrolo[2,3-c]azepine-4,8(1H,5H)-dione

(Compound No. 34)

7-Benzyl-1-(4-chlorobutyl)-6,7-dihydropyrrolo[2,3-c]azepine-4,8(1H,5H)-dione

(Compound No. 24)

1-(4-Bromobutyl)-7-methyl-6,7-dihydropyrrolo[2,3-c]azepine-4,8(1H,5H)-dione

(Compound No. 25)

1-(4-Chloro-(Z)-2-butenyl)-7-methyl-6,7-dihydropyrrolo[2,3-c]azepine-4,8(1H,5H)-dione

(Compound No. 26)

1-(4-Chloro-(E)-2-butenyl)-7-methyl-6,7-dihydropyrrolo[2,3-c]azepine-4,8(1H,5H)-dione

(Compound No. 27)

1-(4-Chloro-2-butynyl)-7-methyl-6,7-dihydropyrrolo[2,3-c]azepine-4,8(1H,5H)-dione

(Compound No. 28)

1-(3-Chloropropyl)-7-methyl-6,7-dihydropyrrolo[2,3-c]azepine-4,8(1H,5H)-dione

(Compound No. 29)

1-(5-Chloropentyl)-7-methyl-6,7-dihydropyrrolo[2,3-c]azepine-4,8(1H,5H)-dione

(Compound No. 35)

7-Benzyl-1-(4-bromobutyl)-6,7-dihydropyrrolo[2,3-c]azepine-4,8(1H,5H)-dione

Example 16

Synthesis of7-butyl-1-(4-chlorobutyl)-6,7-dihydropyrrolo[2,3-c]azepine-4,8(1H,5H)-dione(Compound No. 33)

A suspension of 16.47 g (74.48 mmol) of Compound No. 20 obtained inExample 11, 38.46 g (224 mmol) of 1-bromo-4-chlorobutane and 31.00 g(224 mmol) of potassium carbonate in 200 ml of acetone was stirred for20 hours.

The reaction mixture was filtered to remove any insoluble matter and thesolvent and excess 1-bromo-4-cholorobutane were distilled off underreduced pressure, whereby 22.0 g of the title compound were obtained(yield: 98%).

Appearance: Colorless oil.

Example 17

Synthesis of1-(4-chlorobutyl)-4-hydroxyimino-7-methyl-6,7-dihydropyrrolo[2,3-c]azepin-8(1H,5H)-one(Compound No. 38)

A solution of 4.031 g (15 mmol) of Compound No. 23 obtained in Example14 and 5.212 g (75 mmol) of hydroxylamine hydrochloride in 90 ml ofpyridine was stirred for 18 hours at room temperature.

After the reaction mixture was concentrated under reduced pressure,toluene was added, followed by concentration again under reducedpressure. The residue was added with 200 ml of a 10% aqueous solution ofcitric acid and then extracted with chloroform. The extract was washedwith saturated saline and then dried over anhydrous sodium sulfate.

The solvent was distilled off under reduced pressure and the resultantoil was purified by chromatography on a silica gel column (eluent: 7.5%methanolchloroform), whereby 3.84 g of a colorless oil were obtained(yield: 90%). The oil was crystallized when treated with isopropylether.

Although this compound is sufficiently pure, it can be recrystallizedfrom ethyl acetate if necessary. Appearance: Colorless needle crystals.

Melting point: 113.0°-114.0° C.

Example 18

Compound Nos. 36, 41, 37, 42, 43, 44, 45 and 47 were obtained by usingCompound Nos. 22, 24, 28, 29, 30, 31, 32 and 34 in place of Compound No.23 in the procedure of Example 17.

(Compound No. 36)

1-(4-Chlorobutyl)-4-hydroxyimino-6,7-dihydropyrrolo[2,3-c]azepin-8(1H,5H)-one

(Compound No. 37)

1-(3-Chloropropyl)-4-hydroxyimino-7-methyl-6,7-dihydropyrrolo[2,3-c]azepin-8(1H,5H)-one

(Compound No. 41)

1-(4-Bromobutyl)-4-hydroxyimino-7-methyl-6,7-dihydropyrrolo[2,3-c]azepin-8(1H,5H)-one

(Compound No. 42)

1-(5-Chloropentyl)-4-hydroxyimino-7-methyl-6,7-dihydropyrrolo[2,3-c]azepin-8(1H,5H)-one

(Compound No. 43)

1-(4-Chlorobutyl)-7-ethyl-4-hydroxyimino-6,7-dihydropyrrolo[2,3-c]azepin-8(1H,5H)-one

(Compound No. 44)

1-(4-Chlorobutyl)-4-hydroxyimino-7-propyl-6,7-dihydropyrrolo[2,3-c]azepin-8(1H,5H)-one

(Compound No. 45)

1-(4-Chlorobutyl)-4-hydroxyimino-7-isopropyl-6,7-dihydropyrrolo[2,3-c]azepin-8(1H,5H)-one

(Compound No. 47)

7-Benzyl-1-(4-chlorobutyl)-4-hydroxyimino-6,7-dihydropyrrolo[2,3-c]azepin-8(1H,5H)-one

Example 19

Synthesis of7-butyl-1-(4-chlorobutyl)-4-hydroxyimino-6,7-dihydropyrrolo[2,3-c]azepin-8(1H,5H)-one(Compound No. 46)

A solution of 21.0 g (67.6 mmol) of Compound No. 33 obtained in Example16, 14.1 g (203 mmol) of hydroxylamine hydrochloride and 16.6 g (203mmol) of anhydrous sodium acetate in 150 ml of methanol was stirred for24 hours at room temperature.

The reaction mixture was concentrated under reduced pressure, added with500 ml of chloroform, washed with a 5% aqueous solution of hydrochloricacid, a half-saturated aqueous solution of potassium carbonate andsaturated saline, and then dried over anhydrous sodium sulfate.

The solvent was distilled off under reduced pressure, whereby 19.0 g ofthe title compound were obtained as pale brown crystals (yield: 86%).

Although this compound is sufficiently pure, it can be recrystallizedfrom ethanol if necessary. Appearance: Pale brown needle crystals.

Melting point: 133°-136° C.

Example 20

Synthesis of1-(4-chlorobutyl)-4-methoxyimino-7-methyl-6,7-dihydropyrrolo[2,3-c]azepin-8(1H,5H)-one(Compound No. 39)

A solution of 210 mg (0.74 mmol) of Compound No. 23 obtained in Example14 and 68 mg (0.82 mmol) of O-methylhydroxylamine hydrochloride in 10 mlof pyridine was stirred for 4 hours at 80° C.

The reaction mixture was concentrated under reduced pressure. Theresidue was added with 20 ml of a half-saturated aqueous solution ofpotassium carbonate and was then extracted with chloroform. The extractwas washed with saturated saline, followed by drying over anhydroussodium sulfate.

The solvent was distilled off under reduced pressure and the resultantoil was purified by chromatography on a silica gel column (eluent: 3:7mixed solvent of ethyl acetate and hexane), whereby 104 mg of the titlecompound were obtained (yield: 47%).

Appearance: Colorless oil.

Example 21

Synthesis of4-benzyloxyimino-1-(4-chlorobutyl)-7-methyl-6,7-dihydropyrrolo[2,3-c]azepin-8(1H,5H)-one(Compound No. 40)

A suspension of 13.44 g (50 mmol) of Compound 23 obtained in Example 14,8.20 g (100 mmol) of sodium acetate and 15.96 g (100 mmol) ofO-benzylhydroxylamine hydrochloride in 250 ml of methanol was stirredfor 4 hours at room temperature.

The solvent was distilled off under reduced pressure, followed by theaddition of 600 ml of ethyl acetate to the residue. The organic layerwas washed with 1N-HCl (three times), H₂ O and saturated saline and wasthen dried over anhydrous sodium sulfate. The solvent was distilled offunder reduced pressure and the resultant pale yellow oil was purified bychromatography on a silica gel column (eluent: 2:3 mixed solvent ofethyl acetate and hexane), whereby 16.20 g of the title compound wereobtained as a colorless oil. The oil was crystallized when treated inisopropyl ether (yield: 87%).

Although this compound is sufficiently pure, it can be recrystallizedfrom isopropyl ether if necessary.

Appearance: colorless prism crystals.

Melting point: 62°-64° C.

Example 22

Synthesis of1-[4-[4-(4-fluorobenzoyl)piperidin-1-yl]butyl]-7-methyl-6,7-dihydropyrrolo[2,3-c]azepine-4,8(1H,5H)-dione(Compound No. 60)

A suspension of 1.57 g (5 mmol) of Compound No. 24 obtained in Example15, 2.07 g (10 mmol) of 4-(4-fluorobenzoyl)piperidine and 1.38 g (10mmol) of potassium carbonate in 60 ml of DMF was stirred for 20 hours at80° C. After allowed to cool down, the reaction mixture was filtered. Asolid matter was washed with ethyl acetate. The filtrate and the washingwere combined together, followed by concentration under reducedpressure. The residue was added with 400 ml of a 3:1 (v/v) mixed solventof ethyl acetate and benzene. The organic layer was washed with water(three times) and saturated saline, and then dried over anhydrous sodiumsulfate.

The solvent was distilled off under reduced pressure and the resultantbrown oil was purified by chromatography on a silica gel column (eluent:5% methanol-chloroform), whereby 1.89 g of the title compound wereobtained (yield: 86%).

Appearance: Yellow oil.

Example 23

Compound Nos. 67, 68 and 69 were obtained by using Compound Nos. 25, 26and 27 in place of Compound No. 24 in the procedure described in Example22.

Further, Compound Nos. 52, 53, 54, 55, 72 and 78 were obtained fromCompound No. 24 and 4-benzylpiperidine,4-[bis(4-fluorophenyl)methylene]piperidine,α,α-bis(4-fluorophenyl)-4-piperidinemethanol,4-(diphenylmethoxy)piperidine, 4-(4-methoxybenzoyl)piperidine and3-benzoylpyrrolidine, respectively.

Further, Compound No. 48 was obtained from Compound No. 35 and4-phenylpiperidine.

(Compound No. 67)

1-[4-[4-(4-Fluorobenzoyl)piperidin-1-yl]-(Z)-2-butenyl]-7-methyl-6,7-dihydropyrrolo[2,3-c]azepine-4,8(1H,5H)-dione

(Compound No. 68)

1-[4-[4-(4-Fluorobenzoyl)piperidin-1-yl]-(E)-2-butenyl]-7-methyl-6,7-dihydropyrrolo[2,3-c]azepine-4,8(1H,5H)-dione

(Compound No. 69)

1-[4-[4-(4-Fluorobenzoyl)piperidin-1-yl]-2-butynyl]-7-methyl-6,7-dihydropyrrolo[2,3-c]azepine-4,8(1H,5H)-dione

(Compound No. 52)

1-[4-(4-Benzylpiperidin-1-yl)butyl]-7-methyl-6,7-dihydropyrrolo[2,3-c]azepine-4,8(1H,5H)-dione

(Compound No. 53)

1-[4-[4-[Bis(4-fluorophenyl)methylene]piperidin-1-yl]butyl]-7-methyl-6,7-dihydropyrrolo[2,3-c]azepine-4,8(1H,5H)-dione

(Compound No. 54)

1-[4-[4-[Bis(4-fluorophenyl)hydroxymethyl]piperidin-1-yl]butyl]-7-methyl-6,7-dihydropyrrolo[2,3-c]azepine-4,8(1H,5H)-dione

(Compound No. 55)

1-[4-[4-(Diphenylmethoxy)piperidin-1-yl]butyl]-7-methyl-6,7-dihydropyrrolo[2,3-c]azepine-4,8(1H,5H)-dione

(Compound No. 72)

1-[4-[4-(4-Methoxybenzoyl)piperidin-1-yl]butyl]-7-methyl-6,7-dihydropyrrolo[2,3-c]azepine-4,8(1H,5H)-dione

(Compound No. 78)

1-[4-(3-Benzoylpyrrolidin-1-yl)butyl]-7-methyl-6,7-dihydropyrrolo[2,3-c]azepine-4,8(1H,5H)-dione

(Compound No. 48)

7-Benzyl-1-[4-(4-phenylpiperidin-1-yl)butyl]-6,7-dihydropyrrolo[2,3-c]azepine-4,8(1H,5H)-dione

Example 24

Synthesis of1-[4-[4-(4-fluorobenzoyl)piperidin-1-yl]butyl]-4-hydroxyimino-7-methyl-6,7-dihydropyrrolo[2,3-c]azepine-8-(1H,5H)-one(Compound No. 61)

A suspension of 2.838 g (10 mmol) of Compound No. 38 obtained in Example17, 4.874 g (20 mmol) of 4-(4-fluorobenzoyl)piperidine hydrochloride and5.528 g (40 mmol) of potassium carbonate in 150 ml of DMF was stirredfor 14 hours at 80° C. The reaction mixture was filtered, a solid matterwas washed with chloroform, and the filtrate and the washing werecombined together, followed by concentration under reduced pressure.

The residue was added with 600 ml of a 2:1 (v/v) mixed solvent of ethylacetate and benzene. The organic layer was washed with a half-saturatedaqueous solution of potassium carbonate, water (three times) andsaturated saline, and was then dried over anhydrous sodium sulfate.

The solvent was distilled off under reduced pressure and the resultantbrown oil was purified by chromatography on a silica gel column (eluent:10% methanol-chloroform), whereby 3.28 g of the title compound wasobtained as a colorless oil. When treated in isopropyl ether, the oilwas crystallized (yield: 72%).

Although the compound is sufficiently pure, it can be recrystallizedfrom isopropanol if necessary.

Appearance: Colorless needle crystals.

Melting point: 166°-168° C.

Example 25

Synthesis of1-[4-[4-(4-fluorobenzoyl)piperidin-1-yl]butyl]-4-hydroxyimino-7-methyl-6,7-dihydropyrrolo[2,3-c]azepin-8(1H,5H)-onep-toluenesulfonate (Compound No. 62)

A mixture of 5.0 g (11.0 mmol) of Compound 61 obtained in Example 24 and2.1 g (11.0 mmol) of p-toluenesulfonic acid monohydrate was heated in120 ml of ethanol, so that the latter compounds were dissolved. Theresultant mixture was allowed to cool down, whereby 6.5 g of the titlecompound were obtained as colorless crystals (yield: 92%).

Appearance: Colorless needle crystals.

Melting point: 197°-198° C.

Example 26

Compound Nos. 58, 59 and 63 were obtained by using Compound Nos. 28, 37and 29 in place of Compound No. 38 in the procedure described in Example24.

Compound No. 73 was also obtained by using 4-(4-chlorobenzoyl)piperidinehydrochloride in place of 4-(4-fluorobenzoyl)piperidine hydrochloride.

Further, Compound No. 66 was obtained from Compound No. 47 and4-(4-fluorobenzoyl)piperidine, and Compound Nos. 70 and 71 from CompoundNos. 24 and 41 and 4-benzoylpiperidine, respectively.

(Compound No. 58)

1-[3-[4-(4-Fluorobenzoyl)piperidin-1-yl]propyl]-7-methyl-6,7-dihydropyrrolo[2,3-c]azepine-4,8(1H,5H)-dione

(Compound No. 59)

1-[3-[4-(4-Fluorobenzoyl)piperidin-1-yl]propyl]-4-hydroxyimino-7-methyl-6,7-dihydropyrrolo[2,3-c]azepin-8(1H,5H)-one

(Compound No. 63)

1-[5-[4-(4-Fluorobenzoyl)piperidin-1-yl]pentyl]-7-methyl-6,7-dihydropyrrolo[2,3-c]azepine-4,8(1H,5H)-dione

(Compound No. 73)

1-[4-[4-(4-Chlorobenzoyl)piperidin-1-yl]butyl]-4-hydroxyimino-7-methyl-6,7-dihydropyrrolo[2,3-c]azepin-8(1H,5H)-one

(Compound No. 66)

7-Benzyl-1-[4-[4-(4-fluorobenzoyl)piperidin-1-yl]butyl]-4-hydroxyimino-6,7-dihydropyrrolo[2,3-c]azepin-8(1H,5H)-one

(Compound No. 70)

1-[4-(4-Benzoylpiperidin-1-yl)butyl]-7-methyl-6,7-dihydropyrrolo[2,3-c]azepine-4,8(1H,5H)-dione

(Compound No. 71)

1-[4-(4-Benzoylpiperidin-1-yl)butyl]-4-hydroxyimino-7-methyl-6,7-dihydropyrrolo[2,3-c]azepin-8(1H,5H)-one

Example 27

Synthesis of1-[4-[4-(4-fluorophenylsulfonyl)piperidin-1-yl]butyl]-4-hydroxyimino-7-methyl-6,7-dihydropyrrolo[2,3-c]azepin-8(1H,5H)-one(Compound No. 87)

A suspension of 150 mg (0.53 mmol) of Compound No. 38 obtained by theprocedure of Example 17, 177 mg (0.63 mmol) of4-(4-fluorophenylsulfonyl)piperidine hydrochloride, 0.22 ml (1.59 mmol)of triethylamine and 149 mg (1.06 mmol) of sodium iodide in 3 ml of DMFwas heated for 25 hours at 80° C. under stirring.

The reaction mixture was then post-treated and purified as in Example24, whereby 230 mg of the title compound were obtained as colorlesscrystals (yield: 89%). Although the compound is sufficiently pure, itcan be recrystallized from methanol-ethanol if necessary.

Appearance: Colorless needle crystals.

Melting point: 190°-192° C.

Example 28

Following the procedure described in Example 27, the following compoundswere prepared from the corresponding various combinations of startingmaterials. Compound Nos. 85 and 86 were obtained from Compound No. 38and 4-[(4-fluorophenyl)thio]piperidine hydrochloride and4-[(4-fluorophenyl)sulfinyl]piperidine hydrochloride, respectively.

Further, Compound Nos. 80, 94 and 88 were obtained from4-(4-fluorobenzoyl)piperidine hydrochloride and Compound Nos. 39, 31 and33, respectively.

(Compound No. 85)

1-[4-[4-[(4-Fluorophenyl)thio]piperidin-1-yl]butyl]-4-hydroxyimino-7-methyl-6,7-dihydropyrrolo[2,3-c]azepin-8(1H,5H)-one

(Compound No. 86)

1-[4-[4-[(4-Fluorophenyl)sulfinyl]piperidin-1-yl]butyl]-4-hydroxyimino-7-methyl-6,7-dihydropyrrolo[2,3-c]azepin-8(1H,5H)-one

(Compound No. 80)

1-[4-[4-[(4-Fluorobenzoyl)piperidin-1-yl]butyl]-4-methoxyimino-7-methyl-6,7-dihydropyrrolo[2,3-c]azepin-8(1H,5H)-one

(Compound No. 94)

1-[4-[4(4-Fluorobenzoyl)piperidin-1-yl]butyl]-7-propyl-6,7-dihydropyrrolo[2,3-c]azepine-4,8(1H,5H)-dione

(Compound No. 88)

7-Butyl-1-[4-[4-(4-fluorobenzoyl)piperidin-1-yl]butyl]-6,7-dihydropyrrolo[2,3-c]azepine-4,8(1H,5H)-dione

Example 29

Synthesis of7-ethyl-1-[4-[4-(4-fluorobenzoyl)piperidin-1-yl]butyl]-4-hydroxyimino-6,7-dihydropyrrolo[2,3-c]azepin-8-(1H,5H)-one(Compound No. 65)

A suspension of 5.062 g (17 mmol) of Compound No. 43, 4.228 g (20.4mmol) of 4-(4-fluorobenzoyl)piperidine, 3.440 g (34 mmol) oftriethylamine and 5.069 g (34 mmol) of sodium iodide in 200 ml of DMFstirred for 20 hours at 80° C.

The reaction mixture was then post-treated and purified as in Example24. Recrystallization from ethanol gave 5.47 g of the title compound(yield: 69%).

Appearance: Colorless needle crystals.

Melting point: 158°-160° C.

Example 30

Following the procedure described in Example 29, the following compoundswere prepared from the corresponding various combinations of startingmaterials.

Compound Nos. 74, 75, 76, 81, 82, 83 and 89 were obtained from4-(4-fluorobenzoyl)piperidine and Compound Nos. 36, 44, 45, 22, 30, 34and 46, respectively.

Further, Compound Nos. 77 and 84 were obtained from Compound No. 38 and3-(4-fluorobenzoyl)piperidine and 4-(4-fluorophenoxy)piperidine,respectively.

(Compound No. 74)

1-[4-[4-(4-Fluorobenzoyl)piperidin-1-yl]butyl]-4-hydroxyimino-6,7-dihydropyrrolo[2,3-c]azepin-8(1H,5H)-one

(Compound No. 75)

1-[4-[4-(4-Fluorobenzoyl)piperidin-1-yl]butyl]-4-hydroxyimino-7-propyl-6,7-dihydropyrrolo[2,3-c]azepin-8(1H,5H)-one

(Compound No. 76)

1-[4-[4-(4-Fluorobenzoyl)piperidin-1-yl]butyl]-4-hydroxyimino-7-isopropyl-6,7-dihydropyrrolo[2,3-c]azepin-8(1H,5H)-one

(Compound No. 81)

1-[4-[4-(4-Fluorobenzoyl)piperidin-1-yl]butyl]-6,7-dihydropyrrolo[2,3-c]azepine-4,8(1H,5H)-dione

(Compound No. 82)

7-Ethyl-1-[4-[4-(4-fluorobenzoyl)piperidin-1-yl]butyl]-6,7-dihydropyrrolo[2,3-c]azepine-4,8(1H,5H)-dione

(Compound No. 83)

7-Benzyl-1-[4-[4-(4-fluorobenzoyl)piperidin-1-yl]butyl]-6,7-dihydropyrrolo[2,3-c]azepine-4,8(1H,5H)-dione

(Compound No. 89)

7-Butyl-1-[4-[4-(4-fluorobenzoyl)piperidin-1-yl]butyl]-4-hydroxyimino-6,7-dihydropyrrolo[2,3-c]azepin-8(1H,5H)-one

(Compound No. 77)

1-[4-[3-(4-Fluorobenzoyl)piperidin-1-yl]butyl]-4-hydroxyimino-7-methyl-6,7-dihydropyrrolo[2,3-c]azepin-8(1H,5H)-one

(Compound No. 84)

1-[4-[4-(4-Fluorophenoxy)piperidin-1-yl]butyl]-4-hydroxyimino-7-methyl-6,7-dihydropyrrolo[2,3-c]azepin-8(1H,5H)-one

Example 31

Synthesis of4-benzyloxyimino-1-[4-[4-(4-fluorobenzoyl)piperidin-1-yl]butyl]-7-methyl-6,7-dihydropyrrolo[2,3-c]azepin-8-(1H,5H)-one(Compound No. 90)

A suspension of 7.48 g (20 mmol) of Compound No. 40 obtained in Example21, 5.85 g (24 mmol) of 4-(4-fluorobenzoyl)piperidine hydrochloride,6.48 g (64 mmol) of triethylamine and 6.00 g (40 mmol) of sodium iodidein 300 ml of acetonitrile was refluxed for 24 hours. The reactionmixture was concentrated under reduced pressure. The residue was addedwith 300 ml of a half-saturated aqueous solution of potassium carbonateand then extracted with dichloromethane (300 ml×twice).

The dichloromethane layer was washed with saturated saline and thendried over anhydrous sodium sulfate. The solvent was distilled off underreduced pressure and the resulting brown oil was purified bychromatography on a silica gel column (eluent: 5% methanol-chloroform),whereby 8.51 g of the title compound were obtained (yield: 78%).

Appearance: Yellow oil.

Example 32

Synthesis of1-[4-[4-[2-(4-fluorophenyl)-1,3-dioxolanyl]piperidin-1-yl]butyl]-4-hydroxyimino-7-methyl-6,7-dihydropyrrolo[2,3-c]azepin-8-(1H,5H)-one(Compound No. 93)

A suspension of 2.838 g (10 mmol) of Compound No. 38 obtained in Example17, 3.016 g (12 mmol) of 4-(4-fluorobenzoyl)piperidine ethyleneacetal,2.024 g (20 mmol) of triethylamine and 2.998 g (20 mmol) of sodiumiodide in 500 ml of acetonitrile was refluxed for 24 hours.

The reaction mixture was concentrated under reduced pressure. Theresidue was added with 300 ml of chloroform, washed with water andsaturated saline, and then dried over anhydrous sodium sulfate. Thesolvent was distilled off under reduced pressure and the resultingyellow oil was purified by chromatography on a silica gel column(eluent: 10% methanol-chloroform), whereby 4.375 g of the title compoundwere obtained as a solid yellow solid (yield: 88%).

Although the compound is sufficiently pure, it can be recrystallizedfrom isopropyl alcohol-isopropyl ether if necessary.

Appearance: Colorless prism crystals.

Melting point: 149.0°-150.5° C.

Example 33

Synthesis of1-[4-(4-cyano-4-phenylpiperidin-1-yl)butyl]-7-methyl-6,7-dihydropyrrolo[2,3-c]azepine-4,8(1H,5H)-dione(Compound No. 56)

The title compound was obtained from Compound No. 23 obtained in Example14 and 4-cyano-4-phenylpiperidine hydrochloride in accordance with theprocedure of Example 29 except that triethylamine was replaced by thesame mole number of potassium carbonate.

Example 34

Following the procedure described in Example 33, Compound Nos. 57 and 79were obtained from the combinations of Compound No. 38 and4-cyano-4-phenylpiperidine hydrochloride and3-(4-fluorobenzoyl)pyrrolidine hydrochloride.

Further, Compound No. 64 was also obtained from the combination ofCompound No. 42 and 4-(4-fluorobenzoyl)piperidine hydrochloride.

(Compound No. 57)

1-[4-(4-Cyano-4-phenylpiperidin-1-yl)butyl]-4-hydroxyimino-7-methyl-6,7-dihydropyrrolo[2,3-c]azepin-8(1H,5H)-one

(Compound No. 79)

1-[4-[3-(4-fluorobenzoyl)pyrrolidin-1-yl]butyl]-4-hydroxyimino-7-methyl-6,7-dihydropyrrolo[2,3-c]azepin-8(1H,5H)-one

(Compound No. 64)

1-[5-[4-(4-Fluorobenzoyl)piperidin-1-yl]pentyl]-4-hydroxyimino-7-methyl-6,7-dihydropyrrolo[2,3-c]azepin-8(1H,5H)-one

Example 35

Synthesis of7-methyl-1-[4-(4-phenylpiperidin-1-yl)butyl]-6,7-dihydropyrrolo[2,3-c]azepine-4,8(1H,5H)-dione(Compound No. 49)

A suspension of 806 mg (3 mmol) of Compound No. 23 obtained in Example14, 1.935 g (12 mmol) of 4-phenylpiperidine and 4.500 g (30 mmol) ofsodium iodide in 70 ml of DMF was stirred for 5 hours at 80° C. Thereaction mixture was allowed to cool down, followed by the addition of500 ml of a 2:1 (v/v) mixed solvent of ethyl acetate and benzene. Theorganic layer was washed with a half-saturated aqueous solution ofpotassium carbonate, water (three times) and saturated saline, and wasthen dried over anhydrous sodium sulfate.

The solvent was distilled off under reduced pressure and the resultantoil was purified by chromatography on a silica gel column (eluent: 5%methanolchloroform), whereby 1.106 g of the title compound were obtainedas a pale yellow oil (yield: 94%).

The title compound which was in the free form was converted to itshydrochloride (Compound No. 50) by a method known per se in the art. Thehydrochloride was recrystallized from isopropanol-isopropyl ether.Appearance: Pale yellow plate crystals.

Melting point: 208°-210° C.

Example 36

Synthesis of4-hydroxyimino-7-methyl-1-[4-(4-phenylpiperidin-1-yl)butyl]-6,7-dihydropyrrolo[2,3-c]azepin-8(1H,5H)-one(Compound No. 51)

A solution of 590 mg (1.5 mmol) of the free compound (Compound No. 49)obtained in Example 35 and 521 mg (7.5 mmol) of hydroxylaminehydrochloride in 40 ml of pyridine was stirred for 16 hours at roomtemperature.

After the reaction mixture was concentrated under reduced pressure,toluene was added. The resultant mixture was concentrated again underreduced pressure. The residue was added with 300 ml of a half-saturatedaqueous solution of potassium carbonate and then extracted withchloroform. The extract was washed with saturated saline and then driedover anhydrous sodium sulfate. The solvent was distilled off underreduced pressure. The resultant oil was purified by chromatography on asilica gel column (eluent: 10% methanolchloroform), whereby 546 mg ofcolorless oil was obtained. The oil was treated in isopropyl ether sothat it was crystallized. Although the compound is sufficiently pure, itcan be recrystallized from isopropanol-ether if necessary.

Appearance: Colorless prism crystals.

Melting point: 164°-165° C.

Example 37

Synthesis of4-acetoxyimino-1-[4-[4-(4-fluorobenzoyl)piperidin-1-yl)butyl]-7-methyl-6,7-dihydropyrrolo[2,3-c]azepin-8(1H,5H)-one(Compound No. 91)

To a solution of 5.00 g (11.0 mmol) of Compound No. 61, which had beenobtained in Example 24, in 50 ml of pyridine, 1.56 ml (22.0 mmol) ofacetyl chloride were added. The resulting mixture was stirred for 3hours at room temperature.

After the reaction mixture was concentrated under reduced pressure, 100ml of water was added, followed by the extraction with 400 ml ofdichloromethane. The organic layer was washed with saturated saline andthen dried over anhydrous sodium sulfate. The solvent was distilled offand the resultant brown oil was purified by chromatography on a silicagel column (eluent: 3% methanol-chloroform), whereby 4.30 g of the titlecompound were obtained as a colorless oil (yield: 79%).

Appearance: Colorless oil.

Example 38

Synthesis of4-benzoyloxyimino-1-[4-[4-(4-fluorobenzoylpiperidin)-1-yl]butyl]-7-methyl-6,7-dihydropyrrolo[2,3-c]azepin-8(1H,5H)-one(Compound No. 92)

To a solution of 227 mg (0.5 mmol) of Compound No. 61, which had beenobtained in Example 24, and 92 mg (0.75 mmol) of benzoic acid in 10 mlof DMF, a solution of 122 mg (0.75 mmol) of diethyl cyanophosphonate in5 ml of DMF and another solution of 152 mg (1.5 mmol) of triethylaminein 5 ml of DMF were added successively and gradually, and the resultantmixture was stirred for 16 hours at room temperature. The reactionmixture was added with 300 ml of a 3:1 (v/v) mixture of ethyl acetateand benzene, washed with a saturated aqueous solution of potassiumcarbonate, water (three times) and saturated saline, and then dried overanhydrous sodium sulfate.

The solvent was distilled off under reduced pressure and the resultantbrown oil was purified by chromatography on a silica gel column (eluent:5% methanol-chloroform), whereby 252 mg of the title compound wereobtained (yield: 90%).

Appearance: Yellow oil.

Example 39

Synthesis of4-benzoyloxyimino-1-[4-[4-(4-fluorobenzoylpiperidin)-1-yl]butyl]-7-methyl-6,7-dihydropyrrolo[2,3-c]azepine-8(1H,5H)-one(Compound No. 92) (Alternative process):

To a solution of 227 mg (0.5 mmol) of Compound 61, which had beenobtained in Example 24, in 10 ml of pyridine, 1 ml of benzoyl chloridewas slowly added dropwise under ice cooling and stirring. After theresultant mixture was stirred for 16 hours at room temperature, thereaction mixture was concentrated under reduced pressure. The residuewas added with 300 ml of ethyl acetate. The organic layer was washedwith a saturated aqueous solution of potassium carbonate (twice), water(twice) and saturated saline, and then dried over anhydrous sodiumsulfate. The solvent was distilled off under reduced pressure and theresulting brown oil was purified by chromatography on a silica gelcolumn (eluent: 5% methanol-chloroform), whereby 240 mg of the titlecompound were obtained (yield: 86%).

Example 40

Synthesis of1-[4-[4-(4-fluorobenzoyl)piperidin-1-yl]butyl]-7-methyl-6,7-dihydropyrrolo[2,3-c]azepine-4,8(1H,5H)-dionebenzylbromide (Compound No. 95)

1.5 ml of benzyl bromide was added to a solution of 31.5 mg (0.072 mmol)of Compound No. 60, obtained in Example 22, in 1 ml of acetone.

The resultant mixture was stirred for 21 hours at room temperature.Benzene and n-hexane were added in suitable amounts, followed bytrituration. Crude crystals thus obtained were collected by filtrationand washed with n-hexane (yield: 36 mg, 82%). They were recrystallizedfrom acetone, whereby the title compound was obtained as colorlesscrystals.

Melting point: 150°-155° C.

Example 41

Compound Nos. 96 and 97 were obtained by changing benzyl bromide tomethyl iodide and ethyl bromide, respectively in Example 40.

(Compound No. 96)

1-[4-[4-(4-Fluorobenzoyl)piperidin-1-yl]butyl]-7-methyl-6,7-dihydropyrrolo[2,3-c]azepine-4,8(1H,5H)-dionemethyliodide.

(Compound No. 97)

1-[4-[4-(4-Fluorobenzoyl)piperidin-1-yl]butyl]-7-methyl-6,7-dihydropyrrolo[2,3-c]azepine-4,8(1H,5H)-dioneethylbromide.

Example 42

Synthesis of4-benzoyloxyimino-1-(4-chlorobutyl)-7-methyl-6,7-dihydropyrrolo[2,3-c]azepine-8(1H,5H)-one(Compound No. 98)

A solution of 4.256 g (15 mmol) of Compound No. 38, which had beenobtained in Example 17, and 2.748 g (22.5 mmol) of benzoic acid in 60 mlof DMF was cooled to 0° C., to which a solution of 3.670 g (22.5 mmol)of diethyl cyanophosphate in 20 ml of DMF and another solution of 2.277g (22.5 mmol) of triethylamine in 20 mZ of DMF were successively andgradually added. The resultant mixture was stirred for 1 hour at thesame temperature and for additional 4 hours at room temperature.

The reaction mixture was concentrated under reduced pressure and 600 mlof a 3:1 (v/v) mixed solvent of ethyl acetate and benzene were added tothe residue. The organic layer was washed with a 10% aqueous solution ofcitric acid, water (three times) and saturated saline and was then driedover anhydrous sodium sulfate. The solvent was thereafter distilled offunder reduced pressure. The resulting brown oil was purified bychromatography on a silica gel column (eluent: 1:1 mixed solvent ofethyl acetate and hexane) and then recrystallized from isopropyl ether,whereby 5.604 g of the title compound were obtained (yield: 87%)

Appearance: Colorless prism crystals.

Melting point: 123.5°-125.0° C.

Example 43

Synthesis of4-benzoyloxyimino-1-[4-[4-(4-fluorobenzoyl)piperidine-1-yl]butyl]-7-methyl-6,7-dihydropyrrolo[2,3-c]azepin-8(1H,5H)-one(Compound No. 92)

A suspension of 3.879 g (10 mmol) of Compound No. 98 obtained in Example42, 2.437 g (10 mmol) of 4-(4-fluorobenzoyl)piperidine hydrochloride,3.000 g (20 mmol) of sodium iodide and 3.036 g (30 mmol) oftriethylamine in 50 ml of CH₃ CN was refluxed for 20 hours.

The reaction mixture was concentrated under reduced pressure. Theresidue was added with 300 ml of a half-saturated aqueous solution ofpotassium carbonate, followed by the extraction with dichloromethane(200 ml×3 times). The dichloromethane layers were combined, washed with200 ml of saturated saline, and then dried over anhydrous sodiumsulfate. The solvent was distilled off under reduced pressure.

The resulting brown oil was purified by chromatography on a silica gelcolumn (eluent: 10% methanolchloroform), whereby 2.953 g of the titlecompound were obtained (yield: 53%).

Data of the compounds obtained in the above examples are summarized inTable 1.

    TABLE 1       Property Melting point NMR.sup.1) IR.sup.2)  Structural Comp'd No.     (recrystallization solvent) (δ ppm 270 MHz) (cm.sup.-1) Yield (%)     formula             15 Pale brownpowder (DMSO-d.sub.6 /TMS)2.71(2H, m), 3.37(2H, m),     6.56(1H, m)6.99(1H, m), 8.32(1H, t, J=4.6Hz),12.16(1H, br.s) (KBr)3200,     1665, 15451480, 1420, 14001365, 1270, 11601075, 1005, 905 65      ##STR11##       16 Colorless needlecrystals175.0-177.0°      C.(chloroform-diisopropyl ether) 2.89(2H, m), 3.27(3H, s), 3.73(2H,     m)6.77(1H, t, J=2.6Hz),6.94(1H, t, J=2.6Hz),10.84(1H, br.) 3425, 2450,     16651620, 1480, 14401365, 1145, 1080945 88      ##STR12##       17 Colorless needlecrystals131.0-133.0° C.(isopropanol)     1.27(3H, t, J=7.3Hz), 2.88(2H, m)3.60-3.82(4H, m), 6.77(1H, t, J=2.6Hz),6     .94(1H, m), 11.0(1H, br.) 3425, 2960, 16651620, 1485, 13701300, 1145,     11101070 80      ##STR13##       18 Colorless needlecrystals144.0-148.0° C.(ethyl acetate)     0.99(3H, t, J=7.5Hz), 1.68(2H, m)2.87(2H, m), 3.61(2H, t, J=7.2Hz),3.70(2     H, m), 6.78(1H, t, J=2.6Hz)6.94(1H, t, J=2.6Hz), 10.64(1H, br.) 3430,     2950, 16701620, 1480, 13701150, 1120, 1070890 79      ##STR14##       19 Colorless needlecrystals155.0-158.0° C.(ethyl acetate)     1.24(6H, d, J=6.6Hz), 2.82(2H, m)3.58(2H, m), 5.05(1H, m), 6.77(1H,     m)6.94(1H, t, J=2.7Hz), 10.42(1H, br.) 3430, 2970, 16651615, 1480,     13601140, 1065, 885 89      ##STR15##       20 Pale brownneedle crystals115.0-118.0° C. 0.97(3H, t,     J=7.3Hz), 1.41(2H, m)1.64(2H, m), 2.86(2H, m)3.64(2H, t, J=7.3Hz),     3.69(2H, m)6.78(1H, m), 6.93(1H, m)10.42(1H, br.s) 3194, 2963, 16601616,     1478, 14261370, 1277, 11551083, 894, 781(KBr) 91      ##STR16##       21 Colorless needlecrystals176.0-179.0° C.(chloroform-hexane)     2.74(2H, m), 3.67(2H, m), 4.87(2H, s)6.77(1H, m), 6.89(1H, t, J=2.6Hz)7.2     2-7.44(5H, m), 11.24(1H, br.) 3420, 1665, 16201480, 1365, 10751025 47      ##STR17##       22 Colorless prismcrystals77.0-78.0° C.(ethyl acetate-hexane)     1.79(2H, m), 1.98(2H, m), 2.83(2H, m)3.42-3.67(4H, m), 4.42(2H, t,     J=7.0Hz)6.74(1H, d, J=3.0Hz), 6.85(1H, d, J=3.0Hz)7.10(1H, br.t) 3415,     2940, 16501480, 1465, 14301375, 1315, 1120 77      ##STR18##       23 Colorless prismcrystals59.0-60.5° C.(ethyl acetate-hexane)     1.80(2H, m), 1.98(2H, m), 2.79(2H, m)3.21(3H, s), 3.54(2H, t, J=6.6Hz)3.7     1(2H, m), 4.36(2H, t, J=7.2Hz)6.65(1H, d, J=2.6Hz), 6.80(1H, d, J=2.6Hz) 2     945, 1660, 16351520, 1485, 14351395, 1375, 13251295, 1110, 1075910 97      ##STR19##        24 Colorless solid 1.80-2.07(4H, m), 2.79(2H, m), 3.21(3H, s)3.40(2H,     t, J=6.3Hz), 3.72(2H, m)4.36(2H, t, J=7.0Hz), 6.65(1H, d, J=2.6Hz)6.80(1H     , d, J=2.6Hz) 2925, 1655, 16301480, 1395, 13201110, 1085, 905 43      ##STR20##       25 Yellow crystals 2.75-2.85(2H, m), 3.20(3H, s)3.65-3.78(2H, m),     4.19(2H, d, J=6Hz)5.08(2H, d, J=6Hz), 5.70-5.92(2H, m)6.67(1H, d,     J=3Hz), 6.83(1H, d, J=3Hz) 1660, 1630 21      ##STR21##       26 Pale yellow oil 2.75-2.85(2H, m), 3.20(3H, s)3.65-3.78(2H, m),     4.04(2H, d, J=6Hz)4.97(2H, d, J=6Hz), 5.60-6.08(2H, m)6.67(1H, d,     J=3Hz), 6.80(1H, d, J=3Hz) 1655, 1630 43      ##STR22##       27 Pale yellow oil 2.80(2H, m), 3.21(3H, s), 3.74(2H, m)4.17(2H, t,     J=2Hz), 5.26(2H, t, J=2Hz)6.68(1H, d, J=3Hz), 7.06(1H, d, J=3Hz) 1660,     1625 46      ##STR23##       28 Colorless needlecrystals85.0-87.0° C.(ethyl acetate)     2.32(2H, m), 2.80(2H, m), 3.21(3H, s)3.53(2H, t, J=6.0Hz), 3.71(2H,     m)4.48(2H, t, J=6.6Hz), 6.67(1H, d, J=2.7Hz)6.86(1H, d, J=2.7Hz) 2950,     1660, 16401485, 1440, 14001380, 1325, 12851145, 1120, 1080920 85      ##STR24##       29 Colorless oil 1.47(2H, m), 1.75-1.90(4H, m)2.77(2H, dd, J=3.9,     6.6Hz), 3.21(3H, s)3.53(2H, t, J=6.6Hz), 3.71(2H, m)4.33(2H, t, J=7.3Hz),      6.64(1H, d, J=2.7Hz)6.79(1H, d, J=2.7Hz) 2950, 1660, 16401490, 1440,     14001380, 1325, 11201080, 920 90      ##STR25##       30 Colorless needlecrystals58.0-59.0° C.(diisopropyl ether)     1.25(3H, t, J=7.0Hz), 1.80(2H, m)1.97(2H, m), 2.79(2H, m)3.53(2H, t,     J=6.6Hz), 3.57-3.77(4H, m)4.38(2H, t, J=7.3Hz), 6.64(1H, d, J=3.3Hz)6.80(     1H, d, J=3.3Hz) 2930, 1655, 16251480, 1430, 13901375, 1300, 11351110,     910 94      ##STR26##       31 Colorless oil 0.98(3H, t, J= 7.3Hz), 1.66(2H, m)1.81(2H, m),     1.96(2H, m), 2.78(2H, m)3.50-3.58(4H, m), 3.68(2H, m)4.37(2H, t,     J=7.3Hz), 6.64(1H, d, J=3.0Hz)6.80(1H, d, J=3.0Hz) 2940, 1660, 16301480,     1430, 11801270, 1140, 1120930, 895 98      ##STR27##       32 Colorless oil 1.22(6H, d, J=7.3Hz), 1.77(2H, m)1.97(2H, m),     2.75(2H, m), 3.50-3.59(4H, m)4.38(2H, t, J=7.0Hz), 5.04(1H, m),6.64(1H,     d, J=3.0Hz), 6.79(1H, d, J=3.0Hz) 2950, 1660, 16301480, 1460, 14401380,     1320, 11401080, 895 88      ##STR28##       33 Colorless oil 0.97(3H, t, J=7.2Hz), 1.42(2H, m)1.62(2H, m),     1.81(2H, m), 1.96(2H, m)2.78(2H, m), 3.52(2H, t, J=6.5Hz)3.58(2H, m),     3.59(2H, t, J=7.2Hz)4.37(2H, t, J=7.3Hz), 6.65(1H, d, J=3.0Hz)6.79(1H,     d, J=3.0Hz) 2957, 1662, 16321486, 1433, 13751241, 1209, 910781(film) 98      ##STR29##       34 Colorless oil 1.82(2H, m), 2.00(2H, m), 2.63(2H, m)3.56(2H, t,     J=6.6Hz), 3.65(2H, m)4.43(2H, t, J=7.0Hz), 4.80(2H, s)6.65(1H, d,     J=2.7Hz), 6.82(1H, d, J=2.7Hz)7.28-7.42(5H, m) 2920, 1655, 16251475,     1420, 13951370, 1135, 980 96      ##STR30##       35 Colorless oil 1.75-2.08(4H, m), 2.62(2H, m)3.38(2H, t, J=6.3Hz),     3.65(2H, m)4.43(2H, t, J=6.9Hz), 4.80(2H, s)6.65(1H, d, J=2.6Hz),     6.82(1H, d, J=2.6Hz)7.20-7.45(5H, m)  2900, 1655, 16251475, 1370, 980 63      ##STR31##       36 Colorless platecrystals158.5-159.5° C.(chloroform-hexane)     1.77(2H, m), 1.93(2H, m), 2.97(2H, m)3.42(2H, m), 3.52(2H, t, J=6.6Hz)4.3     5(2H, t, J=7.0Hz), 6.44(1H, d, J=2.7Hz)6.82(1H, d, J=2.7Hz), 7.06(1H, d,     J=5.9Hz)9.89(1H, s) 3570, 3415, 16451497, 1460, 1350995, 940 87      ##STR32##       37 Colorless prismcrystals158.0-161.0° C.(ethyl acetate)     2.28(2H, m), 2.98(2H, m), 3.13(3H, s)3.51(2H, t, J=6.6Hz), 3.57(2H,     m)4.42(2H, t, J=6.6Hz), 6.40(1H, d, J=3.0Hz)6.82(1H, d, J=3.0Hz),     7.94(1H, br.s) 3580, 1635, 14801440, 1400, 13651350, 1080, 1000 960,     940, 900 86      ##STR33##       38 Colorless needlecrystals113.0-114.0° C.(ethyl acetate)     1.77(2H, m), 1.93(2H, m), 2.98(2H, m)3.13(3H, s), 3.51(2H, t, J=6.3Hz)3.5     8(2H, m), 4.31(2H, t, J=6.9Hz)6.39(1H, d, J=2.6Hz), 6.76(1H, d, J=2.6Hz)9     .33(1H, br.s) 3555, 3250, 29301620, 1475, 13951360, 960, 940 90      ##STR34##       39 brown oil 1.78(2H, m), 1.93(2H, m), 2.90(2H, m)3.11(3H, s),     3.49-3.56(4H, m)3.94(3H, s), 4.30(2H, t, J=7.2Hz)6.43(1H, d, J=3.0Hz),     6.76(1H, d, J=3.0Hz) 2950, 1630, 14851450, 1410, 13701050, 940, 880850     47      ##STR35##       40 Colorless prismcrystals62.0-64.0° C.(isopropyl ether)     1.76(2H, m), 1.97(2H, m), 2.94(2H, m)3.10(3H, s), 3.46-3.59(4H, m)4.30(2H     , t, J=6.9Hz), 5.18(2H, s)6.43(1H, d, J=3.0Hz)6.75(1H, d, J=3.0Hz)7.26-7.     45(5H, m) 2933, 1626, 15301487, 1483, 13671245, 1077, 1021942, 774,     703(KBr) 87      ##STR36##       41 Colorless solid 1.78-2.03(4H, m), 2.98(2H, m), 3.13(3H, s)3.39(2H,     t, J=6.3Hz), 3.58(2H, m)4.31(2H, t, J=6.6Hz), 6.39(1H, d, J=3.0Hz)6.77(1H     , d, J=3.0Hz), 8.95(1H, br.) 3570, 2940, 16251480, 1435, 14001360, 1075,     995960, 940 26      ##STR37##       42 Colorless platecrystals113.0-115.0° C.(ethyl acetate)     1.44(2H, m), 1.73-1.86(4H, m), 2.97(2H, m)3.13(3H, s), 3.52(2H, t,     J=6.6Hz)3.58(2H, m), 4.28(2H, t, J=7.3Hz)6.38(1H, d, J=2.6Hz), 6.76(1H,     d, J=2.6Hz)8.55(1H, br.s) 3570, 1620, 14801440, 1400, 13601350, 1080,     1000960, 940, 900 87      ##STR38##       43 Colorless oil 1.23(3H, t, J=7.0Hz), 1.75(2H, m)1.91(2H, m),     2.99(2H, m), 3.40-3.68(6H, m)4.32(2H, t, J=7.2Hz), 6.39(1H, d, J=3.3Hz)6.     75(1H, d, J=3.3Hz), 9.56(1H, br.s) 3570, 3250, 29401625, 1475, 14351370,     1300, 990950 quantitative      ##STR39##       44 Colorless needle crystals93.0-95.0° C.ethanol-diisopropyl     ether) 0.96(3H, t, J=7.3Hz), 1.56-1.85(4H, m)1.93(2H, m), 2.97(2H, m),     3.43-3.63(6H, m)4.32(2H, t, J=7.2Hz), 6.39(1H, d, J=2.7Hz)6.76(1H, d,     J=2.7Hz), 8.54(1H, br.s) 3560, 2930, 16201470, 1430, 13701100, 1000,     960915 64      ##STR40##       45 Colorless needlecrystals111.0-113.0° C.(diisopropyl ether)     1.20(6H, t, J=6.6Hz), 1.74(2H, m)1.89(2H, m), 2.93(2H, m), 3.46(2H,     m)3.50(2H, t, J=6.6Hz), 4.33(2H, t, J=6.6Hz)4.93(1H, m), 6.38(1H, d,     J=3.0Hz)6.76(1H, d, J=3.0Hz), 8.52(1H, br.s) 3570, 2930, 16101430, 1370,     13401165, 1000, 995910, 870 68      ##STR41##       46 Pale brownneedle crystals133.0-136.0° C.(ethanol) 0.96(3H,     t, J=7.3Hz), 1.39(2H, m)1.61(2H, m), 1.78(2H, m), 1.92(2H, m)2.96(2H,     m), 3.50(4H, t, J=6.6Hz)3.54(2H, m), 4.32(2H, t, J=7.0Hz)6.38(1H, d,     J=2.6Hz)6.75(1H, d, J=2.6Hz), 7.26(1H, br.s) 3250, 2952, 16101530, 1483,     14411368, 1242, 1005940, 780(KBr) 86      ##STR42##       47 Colorless prismcrystals160.0-162.0° C.(chloroform-hexane)     1.80(2H, m), 1.95(2H, m), 2.82(2H, m)3.42-3.61(4H, m), 4.37(2H, t,     J=7.0Hz)4.73(2H, s), 6.39(1H, d, J=2.7Hz)6.78(1H, d, J=2.7Hz), 7.25-7.42(     5H, m)8.87(1H, br.s) 3560, 1620, 14651420, 1350, 1045 96      ##STR43##       48 Colorless oil 1.50-1.70(2H, m), 1.70-1.98(6H, m)2.06(2H, m),     2.35-2.59(3H, m)2.62(2H, m), 3.04(2H, m), 3.66(2H, m)4.42(2H, t,     J=7.3Hz), 4.81(2H, s)6.65(1H, d, J=2.6Hz), 6.85(1H, d, J=2.6Hz)7.12-7.42(     10H, m) 2930, 1660, 16301485, 1435, 13751030 27      ##STR44##       49 Pale yellow oil 1.56(2H, m), 1.69-1.93(6H, m)2.04(2H, dt, J=11.2Hz,     4.0Hz), 2.40(2H, m)2.49(1H, m), 2.79(2H, m), 3.02(2H, m)3.21(3H, s),     3.71(2H, m)4.35(2H, t, J=7.2Hz), 6.64(1H, d, J=2.6Hz)6.81(1H, d,     J=2.6Hz), 7.13-7.35(5H, m) 2930, 1655, 16351480, 1390, 13701320, 1140,     1105905 94      ##STR45##       50 Pale yellow 1.85-2.18(8H, m), 2.45-2.93(5H, m) (KBr)  --  plate     crystals 3.04(2H, m), 3.21(3H, s), 3.52-3.82(4H, m) 3430, 2935, 1655     208.0-210.0° C. 4.32(2H, t, J=7.2Hz), 6.66(1H, m) 1620, 1525,     1480  (isopropanol- 6.86(1H, m), 7.17-7.42(5H, m) 1440, 1400, 1190     diisopropyl ether) 12.03(1H, br.) 1140, 945, 905      51 Colorless prismcrystals164.0-165.0° C.(isopropanol-diethyl     ether) 1.54(2H, m), 1.65-1.95(6H, m), 2.04(2H, m)2.39(2H, m), 2.49(1H,     m), 2.95(2H, m)3.04(2H, m), 3.12(3H, s), 3.56(2H, m)4.30(2H, t, J=7.3Hz),      6.35(1H, d, J=2.6Hz)6.76(1H, d, J=2.6Hz), 7.13-7.35(5H, m)9.22(1H,     br.s) 3550, 2925, 16201475, 1390, 13551340, 1145, 11101060, 950, 935 89      ##STR46##       52 Yellow oil 1.35(2H, m), 1.44-1.70(5H, m)1.70-1.98(4H, m), 2.32(2H,     t, J=7.6Hz)2.53(2H, d, J=6.6Hz), 2.78(2H, m)2.89(2H, m), 3.20(3H, s),     3.70(2H, m)4.32(2H, t, J=7.3Hz),6.62(1H, d, J=2.6Hz)6.78(1H, d, J=2.6Hz),      7.07-7.35(5H, m) 2910, 1650, 16251475, 1385, 13101135, 1100, 1065960,     940 65      ##STR47##       53 Pale yellow oil 1.45-1.62(2H, m), 1.75-1.90(2H, m)2.20-2.55(10H,     m), 2.72-2.85(2H, m)3.20(3H, s), 3.60-3.78(2H, m)4.33(2H, t, J=7Hz),     6.62(1H, d, J=3Hz)6.78(1H, d, J=3Hz), 6.85-7.15(8H, m) 1655, 1630 37      ##STR48##       54 Pale yellow oil 1.40-1.60(4H, m), 1.65-2.05(4H, m)2.25-2.45(3H, m),     2.45-2.68(2H, br.s)2.70-2.82(2H, m), 2.85-3.03(2H, m)3.18(3H, s)3.56-3.78     (2H, m), 4.30(2H, t, J=6Hz)6.61(1H, d, J=3Hz),6.78(1H, d, J=3Hz)6.88-7.08     (4H, m), 7.30-7.55(4H, m) 1655, 1630 45      ##STR49##       55 pale yellow oil 1.42-1.58(2H, m), 1.62-1.98(6H, m)2.06-2.22(2H, m),     2.28-2.40(2H, m)2.66-2.82(4H, m), 3.19(3H, s)3.38-3.50(1H, m), 3.64-3.75(     2H, m)4.32(2H, t, J=6Hz), 5.50(1H, s)6.62(1H, d, J=3Hz), 6.78(1H, d,     J=3Hz)7.18-7.40(10H, m) 1650, 1625 61      ##STR50##       56 Colorless oilHydrochloride:Colorless platecrystals196-200°     C. 1.47-1.63(2H, m), 1.79-1.93(2H, m)2.02-2.16(4H, m), 2.38-2.55(4H,     m)2.79(2H, m), 2.98(2H, m), 3.21(3H, s)3.72(2H, m), 4.36(2H, t, J=7.3Hz)6     .65(1H, d, J=3.3Hz), 6.80(1H, d, J=3.3Hz)7.28-7.53(5H, m) 2940, 2240,     16601635, 1485, 1395910 70      ##STR51##       57 Colorless needlecrystals166.0-168.0°      C.(ethanol) 1.45-1.63(2H,m), 1.73-1.88(2H, m)2.05-2.22(4H, m), 2.40-2.55     (4H, m)2.90-3.05(4H, m), 3.13(3H, s), 3.58(2H, m)4.31(2H, t, J=7.3Hz),     6.36(1H, d, J=2.6Hz)6.77(1H, d, J=2.6Hz), 7.30-7.55(5H, m)8.50(1H, br.s) 3     570, 2940, 22401625, 1480, 1400945, 905 61      ##STR52##       58 Brown oil 1.80-1.90(4H, m), 1.95-2.20(4H, m)2.34(2H, m), 2.78(2H,     m), 2.92-3.02(2H, m)3.21(3H, s), 3.15-3.27(1H, m), 3.71(2H, m)4.38(2H,     m), 6.63(1H, d, J=3.0Hz)6.84(1H, d, J=3.0Hz), 7.14(2H, t, J=8.6Hz)7.96(2H     , m) 2940, 1680, 16001635, 1660, 14801395, 1375, 13201155, 975, 910 33      ##STR53##       59 Colorless needlecrystals194.0-197.0°      C.(methanol) 1.77-1.95(4H, m), 1.90-2.18(4H, m)2.36(2H, t, J=7.3Hz),     2.90-3.02(4H, m)3.12(3H, s), 3.20(1H, m), 3.55(2H, m)4.31(2H, m),     6.35(1H, d, J=2.6Hz)6.78(1H, d, J=2.6Hz), 7.13(2H, t, J=8.6Hz)7.95(2H,     m), 10.10(1H, br.s) 3570, 2940, 16801625, 1600, 14801400, 1350, 1160975,     900 69      ##STR54##       60 Pale yellow oil 1.53(2H, m), 1.72-1.92(6H,m)1.97-2.17(2H, m),     2.38(2H, t, J=7.3Hz)2.77(2H, m), 2.96(2H, m)3.10-3.30(4H, m, s at 3.21),     3.72(2H, m)4.35(2H, t, J=7.3Hz), 6.63(1H, d, J=2.6Hz)6.80(1H, d,     J=2.6Hz), 7.13(2H, t, J=8.6Hz),7.96(2H, m) 2930, 1660, 16351600, 1485,     13951155, 975 86      ##STR55##       61 Colorless needlecrystals166.0-168.0° C.(isopropanol)     1.54(2H, m), 1.67-2.00(6H, m), 2.13(2H, m)2.40(2H, t, J=7.6Hz), 2.80-3.08     (4H, m)3.12(3H, s), 3.21(1H, quint., J=7.3Hz)3.56(2H, m), 4.28(2H, t,     J=6.9Hz)6.35(1H, d, J=2.6Hz), 6.75(1H, d, J=2.6Hz)7.13(2H, t, J=6.9Hz)7.9     6(2H, dd, J=8.6Hz, 5.6Hz)10.16(1H, br.s) 3550, 2925, 16751615, 1590,     1     1470390, 1145, 965935 72      ##STR56##       62 Colorless needlecrystals197.0-198.0°      C.(ethanol) (DMSO-d.sub.6 /TMS)1.05-2.10(8H, m), 2.29(3H, s), 2.81(2H,     m)2.95-3.20(4H, m), 3.02(3H, s)3.40-3.60(4H, m), 3.72(1H, m), 4.23(2H,   6     m).28(1H, d, J=2.6Hz), 7.04(1H, d, J=2.6Hz)7.11(2H, d, J=7.9Hz),     7.38(2H, m)7.50(2H, d, J=7.9Hz), 8.10(2H, m)8.98(1H, br.s), 10.95(1H, s) 3     182, 3029, 16721598, 1538, 14961439, 1404, 12331163, 1116, 1011947,     678(KBr) --      ##STR57##     .sup.1) Measured in CDCl.sub.3 /TMS unless otherwise specifically     indicated.     .sup.2) Measured as chloroform solution unless otherwise specifically     indicated.

Test

With respect to the compounds of the present invention, their anti-α₁action and anti-serotonin action were investigated by the testingmethods which will be described below. The test results of somerepresentative compounds are summarized in Table 2.

(1) Anti-α₁ action

The thoracic aorta of each Hartley male guinea pig (body weight: 300-500g) was excised. The sample cut in a helical form was suspended under 1 gload in a Magnus cylinder filled with the Tyrode solution of 37° C.which had been saturated with a mixed gas consisting of 95% O₂ +5 CO₂.Using an isometric transducer (TB-612J/NIHON KOHDEN) and a pressurepreamplifier (AP-620G/NIHON KOHDEN), variations in tension weremeasured. The measurement results were recorded on a thermal pen-writingrecorder (WT-647G/NIHON KOHDEN). Taking the tonic contraction induced by10⁻⁵ M norepinephrine (NE) as 100%, the percent contractions uponaddition of each test drug at 10⁻⁸ and 10⁻⁷ M were determined as anti-α₁action.

(2) Anti-serotonin action (anti-5-HT action)

The superior mesenteric artery of each Hartley male guinea pig (bodyweight: 300-500 g) was excised. The sample cut in a helical form wassuspended under 0.3 g load in a Magnus cylinder filled with the Tyrodesolution of 37° C. which had been saturated with a mixed gas consistingof 5% CO₂ +95% O₂. Using an isometric transducer (UL-10/SHINKOH K.K.)and a pressure preamplifier (DSA-605A/SHINKOH K.K.), variations intension were measured. The measurement results were recorded on apen-writing recorder (VP-6537A/NATIONAL K.K.). Taking the phasiccontraction induced by 10⁻⁵ M serotonin as 100%, the percentcontractions in the presence of each test drug at 10⁻⁷ and 10⁻⁶ M weredetermined as anti-5-HT action.

                  TABLE 2                                                         ______________________________________                                                            Anti α.sub.1 action                                                                 Anti 5-HT action                              Comp'd              (% of Control)                                                                            (% of Control)                                No.    Form         10.sup.-8 M                                                                           10.sup.-7 M                                                                         10.sup.-7 M                                                                          10.sup.-6 M                          ______________________________________                                        48     Free         77.4    37.7  88.0   49.0                                 51     Free         74.9    30.8  84.4   54.4                                 54     Hydrochloride                                                                              90.4    26.0  62.9   14.7                                 60     Hydrochloride                                                                              43.9    20.5  62.9   11.8                                 61     Free         44.7    21.4  12.1   4.1                                  62     P-toluenesulfonate                                                                         26.8    17.1  47.4   8.2                                  65     Free         19.5     9.9  19.9   3.6                                  66     Free         19.3    10.4  77.6   6.9                                  75     Free         37.0    17.9  12.9   8.2                                  81     Free         57.5    28.9  57.1   14.3                                 84     Free         86.5    67.0  60.0   3.8                                  91     Free         58.2    35.5  16.1   10.3                                 92     Free         49.3    21.5  48.5   12.5                                 ______________________________________                                    

We claim:
 1. A pyrroloazepine derivative represented by the followingformula (I): ##STR58## wherein R means a hydrogen atom, a linear orbranched C₁₋₆ alkyl group or a C₇₋₁₀ aralkyl group, A denotes a linearor branched C₂₋₁₀ alkylene, alkenylene or alkynylene group, Z stands forO, NOR₁ in which R₁ is a hydrogen atom or an alkyl, aryl or aralkylgroup, or NOCOR₅ in which R₅ is a hydrogen atom or an alkyl, aryl oraralkyl group, and Y means a group ##STR59## R₂ means a hydrogen atom ora cyano group, R₃ and R'₃ may be the same or different and individuallydenote a substituted or unsubstituted phenyl group or a substituted orunsubstituted aralkyl group, and B is an oxygen atom, sulfur atom or acarbonyl group, sulfinyl group, sulfonyl group, a substituted orunsubstituted cyclic or acyclic acetal group or a hydroxymethylene groupwhich may be substituted at the carbon atom thereof by a substituentselected from the group consisting of lower alkyl, phenyl and phenylsubstituted by at least one halogen atom or C₁₋₄ alkoxy group; and nstands for 0 or 1; or a salt thereof.
 2. The pyrroloazepine derivativeof claim 1, wherein in the formula (I), Y is the group ##STR60## inwhich B, R₂, R₃ and n have the same meanings as defined above, or a saltthereof.
 3. The pyrroloazepine derivative of claim 1, wherein in theformula (I), Z is O or NOH, or a salt thereof.
 4. An intermediatesuitable for use in the production of a pharmaceutical product, saidintermediate being represented by the following formula (III): ##STR61##wherein A denotes a linear or branched C₂₋₁₀ alkylene, alkenylene oralkynylene group, R means a hydrogen atom, a linear or branched C₁₋₆alkyl group or a C₇₋₁₀ aralkyl group, and X represents a substituentselected from the group consisting of halogen, methanesulfonyl andp-toluenesulfonyl.
 5. An intermediate suitable for use in the productionof a pharmaceutical product, said intermediate being represented by thefollowing formula (X): ##STR62## wherein A denotes a linear or branchedC₂₋₁₀ alkylene, alkenylene or alkynylene group, R means a hydrogen atom,a linear or branched C₁₋₆ alkyl group or a C₇₋₁₀ aralkyl group, R₁ is ahydrogen atom or an alkyl, aryl or aralkyl group, and X represents asubstituent selected from the group consisting of halogen,methanesulfonyl and p-toluenesulfonyl.
 6. An intermediate suitable foruse in the production of a pharmaceutical product, said intermediatebeing represented by the following formula (XII): ##STR63## wherein Adenotes a linear or branched C₂₋₁₀ alkylene, alkenylene or alkynylenegroup, R means a hydrogen atom, a linear or branched C₁₋₆ alkyl group ora C₇₋₁₀ aralkyl group, R₅ is a hydrogen atom or an alkyl, aryl oraralkyl group, and X represents a substituent selected from the groupconsisting of halogen, methanesulfonyl and p-toluenesulfonyl.
 7. Atherapeutic agent for circulatory disease having anti-α₁ activity andanti-serotonin activity comprising: (a) an effective amount of thepyrroloazepine derivative (I) or a pharmacologically acceptable saltthereof as described in claim 1 and (b) a pharmaceutically acceptablecarrier.
 8. The pyrroloazepine derivative of claim 1, wherein in theformula (I), A denotes a linear or branched C₂₋₁₀ alkylene group.
 9. Anintermediate suitable for use in the production of a pharmaceuticalproduct, said intermediate being represented by the following formula(II'): ##STR64## wherein R' means a linear or branched C₁₋₆ alkyl groupor a C₇₋₁₀ aralkyl group.